https://www.selleckchem.com/pr....oducts/Trichostatin-
e that ADC ST8176AA1 can target epigenetic modulation to ErbB2+ tumors. Interestingly, the amount of HDACi estimated to be delivered at the ST8176AA1 effective dose would correspond to ~1/1,000 of ST7612AA1 effective dose. Therefore, ST8176AA1 is an attractive new therapeutic candidate because it exhibits increased anti-tumor potency compared to trastuzumab by exerting epigenetic modulation at a much safer dose compared to standard HDACi-based therapeutic protocols. Copyright © 2020 Milazzo, Vesci, Anastasi, Chiapparino, Rosi, Gi
Me gusta
Comentario
Compartir
